WEBULL

Assessing Insulet (PODD) Valuation After Omnipod 5 Global Expansion and FDA Win for Type 2 Diabetes

Simply Wall St · 08/25/2025 12:34

If you’ve been following Insulet (PODD) lately, you’ll know there’s plenty of buzz around the stock. The surge in Insulet’s share price has been driven by three impactful events: its Omnipod 5 system secured FDA clearance for type 2 diabetes, the company launched this system in new international markets, and it also introduced Omnipod Discover, a digital platform aimed at further improving patient engagement. For those wondering why Insulet keeps hitting new highs, these moves demonstrate how quickly the company's growth story is evolving.

All of this has translated to strong momentum in the share price, which is now up 77% over the past year. That jump has not happened in a vacuum. Insulet’s focus on market expansion and technology has widened its addressable market and sent a clear signal to investors. While there have been smaller gains over the past month, the longer-term performance has been remarkable and stands out against many peers in the healthcare sector.

After the rally seen this year, the key question now is whether Insulet’s new growth drivers are already fully reflected in its valuation, or if there is still room ahead for upside.

Most Popular Narrative: 6% Undervalued

According to community narrative, Insulet is currently considered to be trading below its fair value. Analysts are projecting upside potential based on accelerated international growth and digital health integration.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market. This supports top-line revenue growth for several years.

Ever wondered what’s driving such a bold valuation? The key factors are aggressive growth forecasts and a future profit profile that some compare to major technology companies. Interested in discovering which financial targets analysts expect Insulet to reach to unlock this potential? Explore the details to understand the powerful factors and underlying numbers influencing this fair value assessment.

Result: Fair Value of $351.91 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, heavy reliance on Omnipod and new market uncertainties could challenge Insulet’s growth trajectory if innovation or reimbursement does not meet expectations.

Find out about the key risks to this Insulet narrative.

Another View: A Premium Price Tag?

Looking from another angle, our DCF model delivers a very different signal. It suggests Insulet may be priced well above its underlying value. Is this a warning sign, or is the model simply not capturing the growth story?

Look into how the SWS DCF model arrives at its fair value.
PODD Discounted Cash Flow as at Aug 2025
PODD Discounted Cash Flow as at Aug 2025
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Insulet for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Insulet Narrative

If you want to dig into the numbers or bring your own perspective, you can craft a complete narrative in just a few minutes. do it your way.

A great starting point for your Insulet research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Great investors never settle for just one opportunity. If you want to stay a step ahead in the market, check out these unique stock collections designed to match your interests and goals. Take action now to spot the companies quietly changing their industries, before the crowds catch on.

  • Unearth dividend-paying businesses with consistent yields when you check out dividend stocks with yields > 3%, and watch your portfolio build steady income, even in uncertain times.
  • Catalyze your investment strategy by targeting sector leaders in healthcare innovation with healthcare AI stocks. This approach allows you to position yourself at the forefront of the AI-driven medical revolution.
  • Go after next-generation tech opportunities by tracking quantum computing stocks, and connect with the companies pioneering tomorrow’s breakthroughs in quantum computing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.